Anifrolumab

Phase 3

ASTRAZENECA PLC (AZNCF)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Active Systemic Lupus Erythematosus

View Full Landscape

Drug Information

Target Indication

Active Systemic Lupus Erythematosus

Clinical Trial

NCT02794285

Last updated: 2/14/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA2/14/2022

Saphnelo

Saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

AZNCF

ASTRAZENECA PLC

Biotechnology•North America•NASDAQ

Related Pipeline

Quetiapine SRPhase 3

Anxiety Disorders

MEDI3250Phase 3

Healthy Japanese Children Age 2 Years Through 6 Years

ParoxetinePhase 3

Generalized Anxiety Disorder

AZD2265Phase 3

Metastatic Castration-resistant Prostate Cancer

CapivasertibPhase 3

Triple Negative Breast Neoplasms

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts